Sign up to save your podcasts
Or
Share Phase 2b Biomarker Analysis: BCMA CAR-T in Myasthenia Gravis
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Phase 2b Biomarker Analysis: BCMA CAR-T in Myasthenia Gravis
BCMA-directed CAR-T therapy shows promise in myasthenia gravis by selectively targeting plasma cells, improving outcomes, and prompting biomarker-guided care, outpatient delivery models, and health system adaptation.
View all episodes
By TheBrief.HealthBCMA-directed CAR-T therapy shows promise in myasthenia gravis by selectively targeting plasma cells, improving outcomes, and prompting biomarker-guided care, outpatient delivery models, and health system adaptation.